Plain-English translation of NCT06235229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which is a type of therapy that uses your own immune cells to fight multiple myeloma—a cancer of blood cells. Researchers take some of your white blood cells, engineer them in the lab to better recognize and attack myeloma cells, and then put them back into your body. This study will help doctors understand if this approach can help patients whose myeloma has stopped responding to other treatments.
Multiple myeloma often comes back or becomes resistant to standard cancer drugs after a few rounds of treatment, leaving patients with very few options. This medication represents a newer approach that uses the body's own immune system, and early results suggest it may help patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
If accepted into the trial, you will first undergo a procedure called leukapheresis, where some of your white blood cells are collected through the bloodstream and sent to a lab to be engineered. While waiting for your cells to be prepared, you may receive other cancer treatments to help manage your disease. Once your engineered cells are ready, you will receive chemotherapy drugs (fludarabine and cyclophosphamide) for three days to prepare your body, followed by an infusion of the new treatment. You will then be monitored closely with regular visits and tests to see how well the treatment works and manage any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China